Exhibit 99.2

UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

The acquisition by BIMI International Medical Inc (“BIMI”or “the Company”) of Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”), a company organized under the laws of the People’s Republic of China (“the “PRC”), closed on October 8,2021.

On September 10, 2021, the Company entered into a stock purchase agreement to acquire Zhuoda (the“Zhuoda SPA”), a distributor of pharmaceuticals and biologicals located in Chongqing, a southwest city of the PRC and Zhuoda’s wholly-owned subsidiary, Chongqing Qianmei Medical Devices Co., Ltd (“Qianmei”), a distributor of medical devices and medical supplies in the PRC. Pursuant to the Zhuoda SPA, BIMI agreed to purchase all the issued and outstanding equity interests in Zhuoda in consideration of US$11,617,500 (RMB 75,000,000). The entire purchase consideration is to be paid in shares of BIMI’s common stock. At the closing, 2,200,000 shares of common stock of BIMI valued by the two parties at RMB 43,560,000, or $3.00 per share (approximately US$6,600,000) were issued as partial consideration for the purchase of Zhuoda. The remainder of the purchase price of approximately US$4,800,000 (RMB 31,680,000), is subject to post-closing adjustments based on the performance of Zhuoda in 2022 and 2023..

The unaudited pro forma condensed combined balance sheet combines the balance sheets of the Company and Zhuoda as of June 30, 2021 and December 31, 2020, giving pro forma effect to the above transaction as if it had occurred on June 30, 2021 and December 31, 2020. The unaudited pro forma condensed combined statement of operations combines the Company’s and Zhuoda’s operations for the six months ended June 30, 2021 and the year ended December 31, 2020, giving effect to the transaction as described on a pro forma basis as if the transaction had been completed on January 1, 2020.

The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. These pro forma financial statements should be read in conjunction with the audited historical financial statements of the Company and the related financial statements for Zhuoda, which are included elsewhere in this current report on Form 8-K.

The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of the operating results or financial position that would have occurred had the acquisition of Zhuoda by the Company occurred on the indicated date, or during the operational periods presented, nor is it necessarily indicative of the future financial position or operating results.

A preliminary allocation of the purchase price has been made to major categories of assets and liabilities in the accompanying pro forma financial statements based on available information. The actual allocation of the purchase price and the resulting effect on income from operations may differ significantly from the pro forma amounts included herein. These pro forma adjustments represent the Company’s preliminary determination of purchase accounting adjustments and are based upon available information and certain assumptions that the Company believes to be reasonable. Consequently, the amounts reflected in the pro forma financial statements are subject to change, and the final amounts may differ substantially.

BIMI INTERNATIONAL MEDICAL, INC.

PRO FORMA CONDENSED COMBINED BALANCE SHEETS

AS OF JUNE 30, 2021

(UNAUDITED)

	BIMI
	International			Zhuoda						Combined
	Medical, Inc			Pharmaceutical		Adjustments				Pro Forma
ASSETS
CURRENT ASSETS
Cash	$	626,554		$	110,473	$	-			$	737,027
Restricted cash		4,660									4,660
Accounts receivable, net		9,281,572			803,778		-				10,085,350
Advances to suppliers		4,501,686			-						4,501,686
Amount due from related parties		41,642			151,455		-				193,097
Inventories		5,116,715			140,591		-				5,257,306
Prepayments and other receivables		6,013,025			229,820						6,242,845
Operating lease-right of use assets		40,489			-						40,489
Total current assets		25,626,343			1,436,117		-				27,062,460
NON-CURRENT ASSETS
Deferred tax assets		184,243			-						184,243
Property, plant and equipment, net		2,677,733			8,230		-				2,685,963
Intangible assets, net		15,035			-		-				15,035
Operating lease-right of use assets		3,666,334			19,440		-				3,685,774
Goodwill		30,442,737			-		5,728,212		(c)		36,170,949
Total non-current assets		36,986,082			27,670		5,728,212				42,741,964
TOTAL ASSETS	$	62,612,425		$	1,463,787	$	5,728,212			$	69,804,424
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term bank borrowings	$	915,876		$	554,171	$	-			$	1,470,047
Convertible promissory notes, net		5,132,530			-		-				5,132,530
Accounts payable, trade		10,859,165			30,762		-				10,889,927
Advances from customers		3,417,049			1,612		-				3,418,661
Amount due to related parties		792,398			112,127		-				904,525
Taxes payable		720,914			16,686		-				737,600
Other payables and accrued liabilities		5,060,442			202,911		4,800,000		(a)		10,063,353
Lease liabilities-current		758,568			5,635		-				764,203
Total current liabilities		27,656,942			923,904		4,800,000				33,380,846
Long-term loans – non current portion		924,071			-		-				924,071
Lease liabilities-non current		3,392,857			16,095		-				3,408,952
TOTAL LIABILITIES		31,973,870			939,999		4,800,000				37,713,869
EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 26,993,988 shares issued and outstanding as of June 30, 2021		24,794			-		2,200		(b)		26,994
Paid-in capital		-			293,251		(293,251	)	(c)		-
Additional paid-in capital		43,618,216			-		1,449,800		(b)(c)		45,068,016
Statutory reserves		2,263,857			6,629		(6,629	)	(c)		2,263,857
Retained earnings (loss)		(16,524,199	)		202,669		(202,669	)			(16,524,199	)
Accumulated other comprehensive income (loss)		1,004,504			21,239		(21,239	)	(c)		1,004,504
Total BIMI International Medical, Inc. equity		30,387,172			523,788		928,212				31,839,172
NONCONTROLING INTERESTS		251,383			-		-				251,383
Total equity		30,638,555			523,788		928,212				32,090,555
Total liabilities and equity	$	62,612,425		$	1,463,787	$	5,728,212			$	69,804,424

See accompanying notes to the unaudited pro forma condensed combined financial statements

2

BIMI INTERNATIONAL MEDICAL, INC.

PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

FOR SIX MONTHS ENDED JUNE 30, 2021

(UNAUDITED)

	BIMI
	International			ZHUODA						Combined
	Medical, Inc			Pharmaceutical			Adjustments			Pro Forma
REVENUES	$	11,424,991		$	940,438		$	-		$	12,365,429
											-
COST OF REVENUES		8,867,894			759,062			-			9,626,956
											-
GROSS PROFIT		2,557,097			181,376			-			2,738,473
											-
OPERATING EXPENSES:											-
Sales and marketing		1,227,014			79,833			-			1,306,847
General and administrative		4,720,915			95,826			-			4,816,741
Total operating expenses		5,947,929			175,659			-			6,123,588
											-
INCOME (LOSS) FROM OPERATIONS		(3,390,832	)		5,717			-			(3,385,115	)
											-
OTHER INCOME (EXPENSE)											-
Interest expense		(138,237	)		(9,899	)		-			(148,136	)
Other income (expense)		(5,293	)		654			-			(4,639	)
Total other income (expense), net		(143,530	)		(9,245	)					(152,775	)
LOSS BEFORE INCOME TAXES		(3,534,362	)		(3,528	)		-			(3,537,890	)
PROVISION FOR INCOME TAXES		32,003			-			-			32,003
NET INCOME (LOSS) FROM CONTINUING OPERATIONS		(3,566,365	)		(3,528	)		-			(3,569,893	)
DISCONTINUED OPERATIONS
Loss from discontinued operations		-			-			-			-
NET LOSS		(3,566,365	)		(3,528	)		-			(3,569,893	)
Less: net income (loss) attributable to non-controlling interest		42,861			-			-			42,861
NET LOSS ATTRIBITABLE TO BIMI INTERNATIONAL MEDICAL, INC.	$	(3,609,226	)	$	(3,528	)	$	-		$	(3,612,754	)
COMPREHENSIVE INCOME (LOSS)
NET LOSS	$	(3,566,365	)	$	(3,528	)	$	-		$	(3,569,893	)
OTHER COMPREHENSIVE INCOME (LOSS)					-						-
Foreign currency translation adjustment		1,112			30,829						31,941
TOTAL COMPREHENSIVE INCOME (LOSS)	$	(3,565,253	)	$	27,301		$	-		$	(3,537,952	)
Less: comprehensive income (loss) attributable to non-controlling interest		56			-			-			56
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIMI INTERNATIONAL MEDICAL INC.	$	(3,565,309	)	$	27,301		$	-		$	(3,538,008	)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK Outstanding
Basic and diluted		20,859,159			-			2,200,000	(b)		23,059,159
LOSS PER SHARE
Continuing operations – basic and diluted	$	(0.17	)	$	-		$	-		$	(0.15	)
Discontinued operations – basic and diluted	$			$	-		$	-		$	-
Net loss – basic and diluted	$	(0.17	)	$	-		$	-		$	(0.15	)

See accompanying notes to the unaudited pro forma condensed combined financial statements

3

BIMI INTERNATIONAL MEDICAL, INC.

PRO FORMA CONDENSED COMBINED BALANCE SHEETS

AS OF DECEMBER 31, 2020

(UNAUDITED)

	BIMI
	International			Zhuoda							Combined
	Medical, Inc			Pharmaceutical			Adjustments				Pro Forma
ASSETS
CURRENT ASSETS
Cash	$	135,309		$	10,812		$	-			$	146,121
Accounts receivable, net		6,686,552			772,485			-				7,459,037
Advances to suppliers		2,693,325			-			-				2,693,325
Amount due from related parties		-			596,579			-				596,579
Inventories		735,351			207,881			-				943,232
Prepayments and other receivables		14,880,526			255,893			-				15,136,419
Operating lease-right of use assets		53,425			-			-				53,425
Total current assets		25,184,488			1,843,650			-				27,028,138
NON-CURRENT ASSETS
Property, plant and equipment, net		910,208			8,656			-				918,864
Operating lease-right of use assets		-			22,031			-				22,031
Goodwill		6,914,232			-			5,776,062		(c)		12,690,294
Deferred tax assets		193,211			-			-				193,211
Total non-current assets		8,017,651			30,687			5,776,062				13,824,400
TOTAL ASSETS	$	33,202,139		$	1,874,337		$	5,776,062			$	40,852,538
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term bank borrowings	$	904,228		$	571,656		$	-			$	1,475,885
Long-term loans due within one year		34,201			-			-				34,201
Convertible promissory notes, net		3,328,447			-			-				3,328,447
Accounts payable, trade		5,852,050			136,076			-				5,988,126
Advances from customers		194,086			27,559			-				221,645
Amount due to related parties		226,514			142,951			-				369,464
Taxes payable		773,649			(1,122	)		-				772,527
Other payables and accrued liabilities		4,228,976			497,825			4,800,000		(a)		9,526,801
Lease liabilities-current		23,063			4,051			-				27,114
Total current liabilities		15,565,214			1,378,996			4,800,000				21,744,210
Long-term loans – non-current portion		720,997			-			-				720,997
Lease liabilities- non-current		22,457			19,403			-				41,860
TOTAL LIABILITIES		16,308,668			1,398,399			4,800,000				22,507,067
EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 15,254,587 shares issued and outstanding as of December 31, 2020		13,254			-			2,200		(b)		15,454
Paid-in capital		-			293,251			(293,251	)	(c)		-
Additional paid-in capital		26,344,920			-			1,449,800		(b)(c)		27,794,720
Statutory reserves		2,263,857			2,174			(2,174	)	(c)		2,263,857
Accumulated deficit		(12,914,973	)		164,112			(164,112	)			(12,914,973	)
Accumulated other comprehensive income		1,003,392			16,401			(16,401	)	(c)		1,003,392
Total BIMI International Medical, Inc. equity		16,710,450			475,938			976,062				18,162,450
NON CONTROLING INTERESTS		183,021			-			-				183,021
Total equity		16,893,471			475,938			976,062				18,345,471
Total liabilities and equity	$	33,202,139		$	1,874,337		$	5,776,062			$	40,852,538

See accompanying notes to the unaudited pro forma condensed combined financial statements

4

BIMI INTERNATIONAL MEDICAL, INC. 

PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 2020

(UNAUDITED)

	BIMI
	International			ZHUODA						Combined
	Medical, Inc			Pharmaceutical			Adjustments			Pro Forma
REVENUES	$	12,844,902		$	940,438		$	-		$	13,785,340
											-
COST OF REVENUES		10,402,085			759,062			-			11,161,147
											-
GROSS PROFIT		2,442,817			181,376			-			2,624,193
OPERATING EXPENSES:
Sales and marketing		783,134			79,833			-			862,967
General and administrative		5,471,964			95,826			-			5,567,790
Total operating expenses		6,255,098			175,659			-			6,430,757
INCOME (LOSS) FROM OPERATIONS		(3,812,281	)		5,717			-			(3,806,564	)
OTHER INCOME (EXPENSE)
Interest income		304									304
Interest expense		(84,913	)		(9,899	)		-			(94,812	)
Exchange gains		547,114			-						547,114
Other income (expense)		(1,953	)		654			-			(1,299	)
Total other income (expense), net		460,552			(9,245	)		-			451,307
LOSS BEFORE INCOME TAXES		(3,351,729	)		(3,528	)		-			(3,355,257	)
PROVISION FOR INCOME TAXES		434,306			-			-			434,306
NET LOSS FROM CONTINUING OPERATIONS		(3,786,035	)		(3,528	)		-			(3,789,563	)
DISCONTINUED OPERATIONS
Income from operations of discontinued operations		1,908,110			-			-			1,908,110
NET LOSS		(1,877,925	)		(3,528	)		-			(1,881,453	)
Less: net income (loss) attributable to non-controlling interest		119,158			-			-			119,158
NET LOSS ATTRIBITABLE TO BIMI INTERNATIONAL MEDICAL, INC.	$	(1,997,083	)	$	(3,528	)	$	-		$	(2,000,611	)
COMPREHENSIVE INCOME (LOSS)
NET LOSS	$	(1,877,925	)	$	(3,528	)	$	-		$	(1,881,453	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment		(941,957	)		30,829			-			(911,128	)
TOTAL COMPREHENSIVE INCOME (LOSS)	$	(2,819,882	)	$	27,301		$	-		$	(2,792,581	)
Less: comprehensive income (loss) attributable to non-controlling interest		(17,113	)		-			-			(17,113	)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIMI INTERNATIONAL MEDICAL INC.	$	(2,802,769	)	$	27,301		$	-		$	(2,775,468	)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING
Basic and diluted		10,672,814			-			2,200,000	(b)		12,872,814
LOSS PER SHARE
Continuing operations - basic and diluted	$	(0.35	)	$	N/A		$	-		$	(0.30	)
Discontinued operations - basic and diluted	$	0.18		$	N/A		$	-		$	0.15
Net loss - basic and diluted	$	(0.18	)	$	N/A		$	-		$	(0.15	)

See accompanying notes to the unaudited pro forma condensed combined financial statements

5

BIMI International Medical, Inc. and Subsidiaries

Notes to Unaudited Pro Forma Condensed Combined Financial Statements

1. Basis of Presentation

The unaudited pro forma condensed combined financial statements were prepared using the acquisition method of accounting under the provision of ASC 805 on the basis of BIMI International Medical Inc. and subsidiaries (“the Company”) as the accounting acquirer of Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). Under the acquisition method, the acquisition date fair value of the gross consideration paid by the Company to close the acquisition was allocated to the assets acquired and liabilities assumed based on their estimated fair value. Management has made significant estimates and assumptions in determining the preliminary allocation of the gross consideration transferred in the unaudited pro forma condensed combined financial information. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amount recorded may differ materially from the information presented.

The pro forma adjustments reflecting the consummation of the acquisition are based on certain currently available information and certain assumptions and methodologies that the Company believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments may be revised as additional information becomes available and alternative valuation methodologies are evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments and it is possible the differences may be material. The Company believes that its assumptions and methodologies provided a reasonable basis for presenting all the significant effects of the acquisition contemplated based on information available to management at the time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.

The unaudited pro forma condensed combined balance sheet combines the Company’s and Zhuoda’s balance sheets as of June 30, 2021 and December 31, 2020 as if the acquisition had occurred on June 30, 2021 and December 31, 2020. The unaudited pro forma condensed combined statement of operations combines the Company’s and Zhuoda’s operations for the six months ended June 30, 2021 and the year ended December 31, 2020, presented as if the acquisition had been completed on January 1, 2020. These unaudited pro forma combined condensed financial statements are based upon the historical financial statements of the Company and Zhuoda after considering the effect of the adjustments described in these footnotes.

The accompanying unaudited pro forma combined financial statements do not give effect to any cost savings, revenue synergies or restructuring costs which may result from the integration of the Company and Zhuoda operations. Further, actual results may be different from these unaudited pro forma combined financial statements. They should be read in conjunction with the historical financial statements and notes thereto of the Company and Zhuoda.

2. Estimated Preliminary Purchase Price Allocation

The preliminary consideration and allocation of the purchase price to the fair value of Zhuoda’s assets acquired and liabilities assumed as if the acquisition date was June 30, 2021 and December 31, 2020 is presented below:

	June 30, 2021		December 31, 2020
Calculation of consideration per the Zhouda SPA
Common shares issuance	$	1,452,000	$	1,452,000
Remaining consideration - Estimated fair value		4,800,000		4,800,000
Total consideration	$	6,252,000	$	6,252,000
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash		110,473	$	10,812
Accounts receivable		803,778		772,485
Amount due from related parties		151,455		596,579
Inventories		140,591		207,881
Prepayments and other receivables		229,820		255,893
Property, plant and equipment, net		8,230		8,656
Operating lease-right of use assets		19,440		22,031
Short-term bank borrowings		554,171		571,656
Accounts payable		30,762		136,076
Advances from customers		1,612		27,559
Amount due to shareholders		112,127		142,951
Taxes payable		16,686		(1,122	)
Other payables and accrued liabilities		202,911		497,825
Lease liabilities-current		5,635		4,051
lease liabilities-non current		16,095		19,403
Total identifiable net assets		523,788		475,938
Goodwill		5,728,212		5,776,062
Net assets acquired	$	6,252,000	$	6,252,000

6

Goodwill represents the excess of the purchase price over the amounts assigned to the fair value of the assets acquired and the assumed liabilities of Zhuoda.

The Company has not completed the detailed valuation necessary to estimate the fair value of the assets acquired and the liabilities assumed and, accordingly, the adjustments to record the assets acquired and liabilities assumed at fair value reflect the best estimate of the Company based on the information currently available and are subject to change once additional analyses are completed. Furthermore, the cash portion of purchase price has not been paid in full yet and the final purchase price may be subject to the certain closing adjustment items pursuant to the Zhouda SPA.

As the goodwill calculation above assumed full payment of the purchase price, the final amount recorded may differ materially from the information presented.

3. Proforma Adjustments

The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the acquisition and has been prepared for informational purposed only.

The historical financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give pro forma effect to events that are directly attributable to the acquisition, factually supportable, and with respect to the statements of operations, expected to have a continuing impact on the results of the Company.

The pro forma adjustments are comprised of the following elements:

(a) Represents the unpaid  consideration that is payable to the former Zhuoda shareholders;

(b) Reclassify the share consideration that has been issued to the former Zhuoda shareholders, 2,200,000 shares issued on September 22, 2021 valued at $1,452,000 (based on the closing market price as reported by NASDAQ) for the shares issued; and

(c) Represents acquisition consideration allocated to assets acquired and liabilities assumed in the acquisition, and the allocation to goodwill, which was the amount that the purchase price exceeded the fair value of the identifiable net assets, and the elimination of the equity of Zhuoda that the Company acquired.

7